ABSTRACT
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. The incidence of metastasis for cSCC is estimated to be around 1.2-5%. Ribosomal protein S6 (p-S6) and the p21 protein (p21) are two proteins that play central roles in other cancers. These proteins may be equally important in cSCC, and together, these could constitute a good candidate for metastasis risk assessment of these patients. We investigate the relationship of p-S6 and p21 expression with the impact on the prognosis of head and neck cSCC (cSCCHN). p-S6 and p21 expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 116 patients with cSCCHN and associations sought with clinical characteristics. Kaplan-Meier estimators and Cox proportional hazard regression models were also used. The expression of p-S6 was significantly inversely associated with tumor thickness, tumor size, desmoplastic growth, pathological stage, perineural invasion and tumor buds. p21 expression was significantly inversely correlated with >6 mm tumor thickness, desmoplastic growth, and perineural invasion. p-S6-negative expression significantly predicted an increased risk of nodal metastasis (HR = 2.63, 95% CI 1.51-4.54; p < 0.001). p21 expression was not found to be a significant risk factor for nodal metastasis. These findings demonstrate that p-S6-negative expression is an independent predictor of nodal metastasis. The immunohistochemical expression of p-S6 might aid in better risk stratification and management of patients with cSCCHN.
Subject(s)
Head and Neck Neoplasms , Lymphatic Metastasis , Skin Neoplasms , Humans , Male , Female , Middle Aged , Aged , Skin Neoplasms/pathology , Skin Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/metabolism , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Prognosis , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Aged, 80 and over , Biomarkers, Tumor/metabolism , Squamous Cell Carcinoma of Head and Neck/metabolism , Squamous Cell Carcinoma of Head and Neck/pathology , Adult , Kaplan-Meier Estimate , Proportional Hazards Models , ImmunohistochemistryABSTRACT
Background: The cause of chondrodermatitis nodularis helicis (CN) (Winkler's disease) is unknown, but potential associations with autoimmune diseases have been suggested in case reports, however, studies with large case series are lacking. Objectives: To clarify the frequency of chronic inflammatory and autoimmune diseases (CADs), and associated gender and age distribution, in a large cohort of patients with CN. Materials & Methods: The frequency of CADs (systemic and cutaneous) was assessed in 215 patients (65.1% males and 34.9% females; median age: 69.6 years) with a histopathological diagnosis of CN (2000-2017). Endocrine diseases were not included. Statistical analysis included Fisher's exact test and multivariate logistic regression analysis. Results: Twenty different CADs were diagnosed in 15.34% patients with CN. The most frequent were polymyalgia rheumatica (six patients), psoriasis (four patients, one with psoriatic arthritis), rheumatoid arthritis (three patients), CREST syndrome (two patients), vitiligo (two patients), and chronic dermatitis (two patients). Several CADs were strongly associated with tobacco smoking. Systemic CADs were more frequent in females (OR: 3.814; CI 1.513-9.613; p = 0.005; multivariate logistic regression analysis). Differences according to age at onset were not significant. Conclusion: We characterize, for the first time, the spectrum of CADs as well as age and gender distribution in patients with CN based on the largest cohort of patients to date. The possible accumulation of different disorders that are strongly associated with tobacco smoking (Buerger's disease, pulmonary Langerhans cell histiocytosis, rheumatoid arthritis, Lupus erythematosus, and others) merits further investigation, but the rarity of some of them makes this challenging.
Subject(s)
Arthritis, Rheumatoid , Autoimmune Diseases , Dermatitis , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/epidemiology , Autoimmune Diseases/complications , Autoimmune Diseases/epidemiology , Dermatitis/complications , Dermatitis/epidemiology , Female , Humans , Inflammation , Male , Retrospective Studies , Spain/epidemiologyABSTRACT
Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan-Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.
Subject(s)
Pharmaceutical Preparations , Psoriasis , Adalimumab , Humans , Psoriasis/drug therapy , Retrospective Studies , Treatment Outcome , Ustekinumab/therapeutic useSubject(s)
Psoriasis , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Humans , Retrospective StudiesABSTRACT
Celiac disease (CD) is an immune-mediated, gluten-induced enteropathy that affects predisposed individuals of all ages. Many patients with CD do not report gastrointestinal symptoms making it difficult to reach an early diagnosis. On the other hand, CD is related to a wide spectrum of extra-intestinal manifestations, with dermatitis herpetiformis (DH) being the best characterized. These associated conditions may be the clue to reaching the diagnosis of CD. Over the last few years, there have been multiple reports of the association between CD and several cutaneous manifestations that may improve with a gluten-free diet (GFD). The presence of some of these skin diseases, even in the absence of gastrointestinal symptoms, should give rise to an appropriate screening method for CD. The aim of this paper is to describe the different cutaneous manifestations that have been associated with CD and the possible mechanisms involved.
Subject(s)
Celiac Disease/diagnosis , Mucous Membrane/pathology , Skin Diseases/diagnosis , Skin/pathology , Alopecia Areata/complications , Alopecia Areata/diagnosis , Celiac Disease/complications , Dermatitis Herpetiformis/complications , Dermatitis Herpetiformis/diagnosis , Dermatitis, Atopic/complications , Dermatitis, Atopic/diagnosis , Diet, Gluten-Free , Gastrointestinal Diseases/complications , Gastrointestinal Diseases/diagnosis , Glutens/administration & dosage , Humans , Psoriasis/complications , Psoriasis/diagnosis , Rosacea/complications , Rosacea/diagnosis , Skin Diseases/complications , Stomatitis, Aphthous/complications , Stomatitis, Aphthous/diagnosis , Urticaria/complications , Urticaria/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/complications , Vasculitis, Leukocytoclastic, Cutaneous/diagnosisABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Ecthyma, Contagious/diagnosis , Parapoxvirus/isolation & purification , BiopsyABSTRACT
No disponible
